Abstract
Methods: Enrolled in this study were 31 patients with different advanced carcinoma: 9 patients were given GEM (1 h i.v. infusion, 1000 mg/m2) followed after 5 min by VNR (10 min i.v. infusion, 25 mg/m2) (GEM-VNR sequence); 17 patients received VNR followed by GEM (VNR-GEM sequence), at the same doses and with the same infusion period; as a control group (GEM), 5 patients were given only single-agent gemcitabine (1 h i.v. infusion, 1000 mg/m2).
Results: GEM serum levels showed higher Cmax and AUCtot in the VNR-GEM protocol than in the GEM-VNR and GEM groups. The GEM pharmacokinetic profile in both schedules showed biphasic elimination, as in monotherapy. VNR concentration/time curves showed rapid plasma clearance and wide interpatient variability in both sequences. VNR Cmaxwas higher in the VNR-GEM group than in GEM-VNR, while VNR AUCtot and Cltot did not differ significantly in the two sequences.
Conclusions: Some pk-values were altered for both GEM and VNR, following the two alternate protocols. A possible rationale for this behaviour is that VNR and GEM may influence each other during liver elimination extraction and metabolism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Storniolo AM, Allerheiligen S, Pearce HL. Preclinical, pharmacologic and phase I studies of gemcitabine. Semin Oncol 1997; 24:2–7.
Eli Lilly and Co. Summary of product characteristics: gemcitabine. UK prescribing information. Eli Lilly 1997.
Gregory RK, Smith IE. Vinorelbine: a clinical review. Br J Cancer 2000; 82: 1907–13.
Rahmani R, Bruno R, Iliadis A et al. Clinical pharmacokinetics of the antitumor drug navelbine. Cancer Res 1987; 47: 5796–9
Chen YM, Peng JW, Perng RP et al. A multicenter phase II study of gemcitabine and vinorelbine in patients with advanced stage IIIB/IV non-small cell lung cancer. Proc Am Soc Clin Oncol 1999; 18: 481 (Abstract).
Cattel L, Recalenda V, Airoldi M et al. A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions. Farmaco 2001; 56: 779–84.
Freeman KB, Anliker S, HamiltonM et al. Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1995; 665: 171–81.
Robieux I, Vitali V, Aita P et al. Sensitive high-performance liquid chromatographic method with fluorescence detection for measurement of vinorelbine plasma concentration. J Chromatogr B 1996; 675: 183–7.
Perez-Manga G, Lluch A, Alba E et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol 2000; 18: 2545–52.
Sorio R, Robieux I, Galligioni E et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997; 33: 301–3.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cattel, L., Airoldi, M., Passera, R. et al. Gemcitabine plus vinorelbine chemotherapy regimens: a pharmacokinetic study of alternate administration sequences. Pharm World Sci 26, 238–241 (2004). https://doi.org/10.1023/B:PHAR.0000035884.89280.8c
Issue Date:
DOI: https://doi.org/10.1023/B:PHAR.0000035884.89280.8c